Teva Pharmaceutical Industries (TEVA) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Teva Pharmaceutical Industries (TEVA) by buying its US-listed ADR shares or fractional shares at any major US broker, through a healthcare or generic-drug ETF that holds it, or as one holding in a thematic basket. Teva is one of the world's largest generic-drug makers, but its investment story now centers on a deliberate shift toward higher-margin branded specialty medicines: neuroscience drugs like AUSTEDO and UZEDY, the migraine treatment AJOVY, and a growing biosimilars portfolio. The single most important thing to understand is the ongoing turnaround: management's Pivot to Growth strategy is trying to grow innovative products faster than the mature generics business declines, while paying down a large debt load left from past acquisitions and settling legacy litigation.
TEVA stock price
As of 2026-07-14, Teva Pharmaceutical Industries (TEVA) last closed at $31.83, up 93.8% over the past year. Over the past 52 weeks it has traded between $15.38 and $36.34.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Teva Pharmaceutical Industries 's investor relations page. Walnut is informational, not investment advice.
What does Teva Pharmaceutical Industries (TEVA) do?
Teva Pharmaceutical Industries is a global pharmaceutical company and one of the largest generic-drug manufacturers in the world, headquartered in Israel and listed in the US as an ADR. Its business has two broad pillars: a large, mature generics and biosimilars operation that supplies affordable versions of off-patent medicines across many markets, and a growing innovative (branded specialty) portfolio concentrated in neuroscience and respiratory conditions. Key branded products include AUSTEDO for movement disorders such as tardive dyskinesia and Huntington's chorea, UZEDY, a long-acting injectable for schizophrenia, and AJOVY for migraine prevention. Teva also runs an active pharmaceutical ingredients business and a biosimilars program targeting hundreds of millions in revenue by 2027.
The strategic picture in 2026 is a multi-year turnaround called Pivot to Growth. After years weighed down by debt from its 2016 Allergan generics acquisition, generic price erosion, and large opioid and other litigation settlements, Teva has been shifting its mix toward higher-margin innovative medicines while deleveraging. In Q1 2026 the innovative portfolio grew sharply, with AUSTEDO, UZEDY, and AJOVY all posting strong double-digit revenue gains, and the company reiterated financial targets for mid-single-digit revenue growth, a roughly 30% operating margin, and a lower net-debt-to-EBITDA ratio. In June 2026 Teva closed its acquisition of Emalex Biosciences, adding the late-stage Tourette-syndrome candidate ecopipam to its neuroscience pipeline. The bet is that branded growth and biosimilars can more than offset a slowly declining generics base while the balance sheet keeps improving.
What's driving Teva Pharmaceutical Industries (TEVA)?
1. Innovative neuroscience growth engine
Teva's branded neuroscience franchise is the core of the growth thesis. AUSTEDO for movement disorders is the flagship, posting strong double-digit revenue growth, joined by UZEDY, a long-acting schizophrenia injectable growing even faster off a smaller base, and AJOVY for migraine prevention. Collectively the innovative portfolio grew sharply year over year in Q1 2026. These higher-margin branded products are what management is counting on to lift overall profitability and shift the company's mix away from commoditized generics.
2. Pivot to Growth and deleveraging
The Pivot to Growth strategy aims for mid-single-digit revenue growth, a roughly 30% operating margin, a net-debt-to-EBITDA ratio around 2.0x, and high cash-to-earnings conversion over its plan horizon. After years of carrying heavy debt from the Allergan generics deal, Teva has prioritized paying down borrowings and improving its financial profile. Continued deleveraging reduces interest costs and financial risk, and hitting these margin and leverage targets is central to how the market judges the turnaround's success.
3. Biosimilars and pipeline expansion
Teva is building a biosimilars business it has targeted to reach roughly $800 million in revenue by 2027, offering lower-cost versions of complex biologic drugs as they lose exclusivity. It complements this with capital-efficient business development: in June 2026 it closed the Emalex Biosciences acquisition, adding ecopipam, a first-in-class candidate for Tourette syndrome with an NDA anticipated later in 2026. These moves broaden the innovative pipeline and give Teva additional growth drivers beyond its current flagship brands.
4. Stable generics cash base
Teva's large generics and active-ingredient operations remain a substantial, cash-generative foundation even as the strategic spotlight moves to branded medicines. A broad global generics portfolio funds the pivot and deleveraging, and Teva's scale in manufacturing and distribution is a genuine competitive asset. The challenge is that generic pricing tends to erode over time, so the segment is managed for durable cash flow and selective complex-generic launches rather than for growth.
What are the risks to Teva Pharmaceutical Industries (TEVA)?
Teva carries meaningful risks despite the improving story. Its debt load, though reduced, remains large, so higher interest costs or a stumble in cash generation could slow deleveraging. The generics business faces ongoing price erosion and intense competition, and much depends on a concentrated set of branded products: any safety issue, competitive launch, or slower uptake for AUSTEDO, UZEDY, or AJOVY would hurt the growth thesis. As an Israel-based ADR, the stock carries currency and geopolitical exposure. Teva also has a history of large litigation and regulatory matters, including opioid-related settlements paid out over many years, which absorb cash. Pipeline bets like ecopipam still require regulatory approval and successful commercialization, and acquisitions add integration risk. Drug-pricing policy and reform in the US and other markets could pressure both the generic and branded businesses.
How is Teva Pharmaceutical Industries (TEVA) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Teva Pharmaceutical Industries 's investor relations page or your broker.
- Quarterly revenue (Q1 2026): Roughly $4 billion, ahead of expectations
- Adjusted (non-GAAP) EPS (Q1 2026): Modest and up low-single-digits year over year, beating consensus
- Innovative portfolio growth: Strong, up roughly 40% year over year, led by AUSTEDO
- Profitability targets: Management targets around a 30% operating margin under Pivot to Growth
- Leverage: Elevated but declining; net-debt-to-EBITDA targeted near 2.0x
- Dividend: None currently; capital is directed to deleveraging and growth investment
These figures are approximate, qualitative, and tied to the asOf date; verify live numbers before acting. Teva trades largely on the credibility of its turnaround, so the market weighs innovative-product momentum and debt reduction more than any single quarter's headline number. Because reported (GAAP) results can be distorted by litigation charges, impairments, and amortization, investors often focus on adjusted metrics; compare both, and confirm current leverage and guidance directly from company filings.
Who competes with Teva Pharmaceutical Industries (TEVA)?
Global generic and biosimilar makers
Teva's generics and biosimilars business competes with large generic manufacturers such as Viatris, Sandoz, Amneal, and India-based producers like Dr. Reddy's and Sun Pharma. These rivals contend on price, breadth of portfolio, manufacturing scale, and speed to market as drugs lose exclusivity, and the segment is characterized by ongoing price erosion that pressures margins across all players.
Branded neuroscience and specialty pharma
For its innovative franchise, Teva competes with specialty and branded drugmakers in neuroscience and related areas, including Neurocrine Biosciences (a direct rival in movement disorders with a competing VMAT2 inhibitor), plus larger pharma companies with CNS, psychiatry, and migraine portfolios. Here competition is about clinical differentiation, pipeline depth, and commercial reach rather than price.
Large diversified pharmaceutical companies
As Teva shifts toward higher-margin branded medicines, it increasingly competes for pipeline assets, talent, and prescriber attention with big diversified pharma such as Pfizer, Novartis, and AbbVie. These companies have far larger R&D budgets and balance sheets, so Teva differentiates through focus, capital-efficient deal-making, and its established position in specific therapeutic niches.
How to invest in Teva Pharmaceutical Industries (TEVA)
There are three common ways to get TEVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TEVA sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where TEVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Teva Pharmaceutical Industries (TEVA)
Teva is a turnaround story: a generics giant pivoting to higher-margin specialty medicines led by AUSTEDO, with improving profitability and a growing biosimilar and neuroscience pipeline, balanced against a heavy debt load, generic pricing pressure, and legacy legal overhangs.
Build a basket around TEVA with Walnut
Use Teva Pharmaceutical Industries as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TEVA a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a credible turnaround: fast-growing branded neuroscience drugs led by AUSTEDO, a biosimilars ramp, improving margins, and steady deleveraging. The bear case is a still-large debt load, generic price erosion, reliance on a few key products, and legacy litigation. Weigh Teva's turnaround progress against those risks and your own portfolio before deciding.
What does Teva actually do?
+
Teva is a global pharmaceutical company and one of the world's largest generic-drug makers. It has two broad pillars: a large generics and biosimilars business that supplies affordable versions of off-patent medicines, and a growing branded specialty portfolio focused on neuroscience, including AUSTEDO for movement disorders, UZEDY for schizophrenia, and AJOVY for migraine prevention. It also produces active pharmaceutical ingredients.
What is Teva's Pivot to Growth strategy?
+
Pivot to Growth is Teva's multi-year plan to shift its business mix toward higher-margin branded specialty medicines and biosimilars while reducing debt. It targets mid-single-digit revenue growth, a roughly 30% operating margin, a net-debt-to-EBITDA ratio near 2.0x, and strong cash conversion. The idea is to grow innovative products faster than the mature generics base declines, improving both profitability and financial resilience.
Does Teva pay a dividend?
+
Teva suspended its dividend years ago while it worked to pay down the large debt from its Allergan generics acquisition and to fund its turnaround, and it has continued to prioritize deleveraging and growth investment over cash returns. As a result, investors are relying on potential share-price appreciation rather than income. Always confirm the company's current capital-return policy before assuming any payout.
What was the Emalex acquisition?
+
In June 2026 Teva closed its acquisition of Emalex Biosciences, adding the late-stage candidate ecopipam to its neuroscience pipeline. Ecopipam is a first-in-class selective dopamine D1 receptor antagonist for Tourette syndrome that showed positive Phase 3 data, with an NDA anticipated later in 2026. Teva paid roughly $700 million upfront plus potential milestone and royalty payments, part of its capital-efficient business-development approach.
Why does Teva carry so much debt?
+
Much of Teva's debt traces to its 2016 acquisition of Allergan's generics business, a large deal that later coincided with generic price erosion and heavy litigation costs. The company has spent years reducing that debt, and lowering net-debt-to-EBITDA toward around 2.0x is a central pillar of its turnaround. Continued deleveraging cuts interest costs and financial risk, but the balance sheet is still something investors watch closely.
How does drug-pricing pressure affect Teva?
+
Generic drugs face continual price erosion as competitors enter, which pressures Teva's largest business, and government drug-pricing reforms in the US and other markets can affect both its generic and branded products. That backdrop is a key reason Teva is shifting toward higher-margin branded specialty medicines and complex generics, where competition is based more on differentiation than on price. Policy changes remain a genuine uncertainty.
Is TEVA an American company?
+
Teva is headquartered in Israel and its shares trade in the US as an American Depositary Receipt (ADR), which lets US investors buy it like any other US-listed stock. Being an Israel-based ADR adds currency and geopolitical considerations that a purely domestic company would not have. Otherwise it operates globally across many markets in both generics and branded medicines.
How can I get exposure to Teva through an ETF?
+
TEVA appears in various healthcare, pharmaceutical, generic-drug, and broad international or value ETFs, where it sits among many other drug and health-care names. ETF exposure spreads single-stock risk across dozens of holdings but dilutes how much any Teva move affects you. Always check a fund's actual holdings and weighting before assuming it gives you meaningful Teva exposure.
What are the main risks of investing in TEVA?
+
The central risks are a still-large (though shrinking) debt load, ongoing generic price erosion, and reliance on a concentrated set of branded products such as AUSTEDO, where a safety, competitive, or uptake problem would hurt the growth story. Legacy litigation including opioid settlements absorbs cash over years, pipeline bets need regulatory approval, and as an Israel-based ADR the stock carries currency and geopolitical exposure.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Teva Pharmaceutical Industries 's investor relations page or your broker before making investment decisions.